Catalyst Pharma CCO equity canceled in Angelini merger
Catalyst Pharmaceuticals Chief Commercial Officer Jeffrey Del Carmen reported issuer dispositions on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A.
Rhea-AI Filing Summary
Catalyst Pharmaceuticals Chief Commercial Officer Jeffrey Del Carmen reported issuer dispositions on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. He disposed of 14,337 common shares at $31.5000 per share, and all reported restricted stock units and stock options vested in full, were canceled, and converted into rights to receive cash payments calculated using a $31.50 per-share merger price. Following these transactions, he reports no remaining Catalyst equity holdings, including common stock, RSUs, or stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 1,051,183 shares
Disposition
11 txns
Insider
Del Carmen Jeffrey
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 150,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 200,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 135,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 88,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 167,918 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 137,553 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 106,873 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 8,039 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 11,206 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 32,257 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 14,337 | $31.50 | $452K |
Holdings After Transaction:
Options to purchase common stock — 0 contracts (Direct);
Restricted Stock Units — 0 contracts (Direct);
Common Stock, par value $0.001 per share — 0 shares (Direct)
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Common shares disposed: 14,337 shares at $31.5000 per share
Merger per-share price reference: $31.50 per share
RSUs canceled (grant 1): 32,257 RSUs
+5 more
8 metrics
Common shares disposed
14,337 shares at $31.5000 per share
Issuer disposition of common stock on 2026-07-15 in connection with Angelini Pharma S.p.A. acquisition
Merger per-share price reference
$31.50 per share
Used to calculate cash payments for canceled RSUs and stock options at merger closing
RSUs canceled (grant 1)
32,257 RSUs
Restricted Stock Units vested in full and were canceled for cash based on $31.50 per share
RSUs canceled (grant 2)
11,206 RSUs
Additional RSUs vested in full and were canceled for cash at merger closing
RSUs canceled (grant 3)
8,039 RSUs
RSUs vested in full and were canceled and converted into cash rights in the merger
Options canceled (lowest strike block)
200,000 options at $3.4200
Options to purchase common stock canceled and converted into cash based on $31.50 less $3.4200 per share
Options canceled (higher strike block)
167,918 options at $14.1500
Options canceled and converted into cash based on $31.50 less $14.1500 per share
Total dispositions reported
11 transactions
Transaction summary shows 11 dispose transactions, including common stock, RSUs, and stock options
Key Terms
Restricted Stock Units, Disposition to issuer, stock option, Merger, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Disposition to issuer financial
"transaction code D with description "Disposition to issuer" for the securities"
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Merger financial
"in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
Angelini Pharma S.p.A. financial
"acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Catalyst Pharmaceuticals (CPRX) disclose for its Chief Commercial Officer?
Catalyst Pharmaceuticals disclosed that Chief Commercial Officer Jeffrey Del Carmen disposed of 14,337 common shares at $31.5000 per share and had all reported RSUs and stock options canceled for cash in connection with Angelini Pharma’s acquisition of the company, leaving him with no Catalyst equity holdings.
What happened to Jeffrey Del Carmen’s restricted stock units at Catalyst Pharmaceuticals (CPRX)?
Del Carmen’s reported restricted stock units, including blocks of 32,257, 11,206, and 8,039 RSUs, vested in full at the merger and were canceled. Each RSU was converted into a right to receive a cash payment based on the $31.50 per-share merger price.
How were Jeffrey Del Carmen’s stock options in Catalyst Pharmaceuticals (CPRX) treated in the Angelini Pharma acquisition?
Each reported stock option, such as options on 200,000 shares at $3.4200 and 167,918 shares at $14.1500, was canceled and converted into a right to receive cash equal to ($31.50 minus the exercise price) times the option shares, less applicable withholdings.
Does Jeffrey Del Carmen still hold any Catalyst Pharmaceuticals (CPRX) equity after the Angelini merger?
After the Angelini Pharma S.p.A. merger closed, Del Carmen reports zero shares of common stock and no remaining RSUs or stock options. All reported Catalyst equity awards and shares were either disposed of or canceled and converted into cash rights under the merger terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
